SCHEMBL17349750

SCHEMBL17349750

CCCCC(=O)N[C@H]1Cc2cccc(C(=O)OCOC(=O)C(C)(C)C)c2OB1O

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PRKCB P05771 1/20 0.33
▸ PRKCA P17252 1/20 0.33
▸ PRKCH P24723 1/20 0.33
▸ PRKCE Q02156 1/20 0.33
▸ PRKCD Q05655 1/20 0.33
▸ NAMPT P43490 2/20 0.33
▸ TRPA1 O75762 2/20 0.31
▸ MTNR1A P48039 2/20 0.31
▸ MTNR1B P49286 2/20 0.31
▸ CA12 O43570 1/20 0.31
▸ CA1 P00915 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CA7 P43166 1/20 0.31
▸ CA9 Q16790 1/20 0.31
▸ CA14 Q9ULX7 1/20 0.31
▸ ALDH1A1 P00352 1/20 0.31
▸ GAA P10253 1/20 0.31
▸ DRD3 P35462 1/20 0.31
▸ TSHR P16473 1/20 0.31
▸ TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17349756 0.97 NAMPT (0.34) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349986 0.96 NAMPT (0.35) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17337362 0.95 MTNR1A (0.36) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17337366 0.95 MTNR1A (0.36) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL23130069 0.92 PRKCB (0.33) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17347740 0.92 PRKCB (0.33) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349775 0.91 PRKCB (0.34) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17349763 0.91 NAMPT (0.34) NAMPTTRPA1MTNR1AMTNR1BCA12
SCHEMBL17337154 0.91 PRKCB (0.34) PRKCBPRKCAPRKCHPRKCEPRKCD
SCHEMBL17337157 0.91 PRKCB (0.34) PRKCBPRKCAPRKCHPRKCEPRKCD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11008346-B2 Beta-lactamase inhibitors VenatoRx Pharmaceuticals, Inc. (US) 2021-05-18 — — US disclosed
US-20200361962-A1 BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2020-11-19 — — US disclosed
US-20150361107-A1 ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2015-12-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11008346-B2 Beta-lactamase inhibitors MGAM, GAA, LCT PRKCB 2479/4885PRKCA 2852/4885PRKCH 2897/4885
US-20200361962-A1 BETA-LACTAMASE INHIBITORS MGAM, GAA, LCT PRKCB 2479/4885PRKCA 2852/4885PRKCH 2897/4885
US-20150361107-A1 ORALLY BIOAVAILABLE BETA-LACTAMASE INHIBITORS SI, ALPI, GAA PRKCB 3762/4885PRKCA 3994/4885PRKCH 3852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback